Astellas Pharma
DC · 20 filings, 2025
What the money shows
Astellas Pharma reported $3.1M in federal lobbying for 2025 across 20 filings. The filings name 5 lobbying firms, led by TIBER CREEK and TODD Strategy. The filing text lists 6 issue areas.
Sources: Senate LDA · FEC
Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha). via Wikipedia ↗
1Lobbies on
Its filings list: Health Issues · Medicare/Medicaid · Pharmacy · Copyright/Patent/Trademark · Taxation/Internal Revenue Code · Insurance
2Through these firms · 5
3Bills moving in its lanes
No bill names this company outright; these are recent bills in the sectors it lobbies.
- S 5236A bill to amend title XIX of the Social Security Act to ensure Medicaid coverage of mental health services…
- S 5225A bill to amend the Elementary and Secondary Education Act of 1965 to include certain curriculum expenses a…
- S 5227A bill to amend the Internal Revenue Code of 1986 to allow certain distributions from long-term qualified t…
- S 5232A bill to amend the Public Health Service Act to authorize rural residency planning and development grant p…
- S 5224A bill to improve training for airport drivers in the movement area at commercial service airports through…